Pleco Therapeutics

Pleco Therapeutics is a private, preclinical-stage biotech developing its Plecoid™ platform, which targets the tumor microenvironment to remove toxic metals and rebalance protein expression, thereby sensitizing cancers to chemotherapy. The company's lead candidate, PTX-252, is being developed for Acute Myeloid Leukemia (AML), with a positive Pre-IND meeting outcome announced in March 2025. Operating from Amsterdam, Pleco is pre-revenue and strategically targeting high-unmet-need orphan cancers to establish initial proof-of-concept and market value for its novel approach.

Plecoid™ platform: small molecule therapies that modulate the tumor microenvironment by removing toxic metals and rebalancing protein expression to sensitize cancer cells to existing chemotherapy.

Pleco operates in the competitive oncology chemosensitizer and supportive care space. Potential competitors include companies developing agents to modulate the tumor microenvironment, overcome drug resistance, or chelate metals (e.g., for iron overload). It also competes indirectly with all novel AML therapies aiming to improve frontline and relapsed/refractory treatment outcomes.